Latest Insider Transactions at Edwards Lifesciences Corp (EW)
This section provides a real-time view of insider transactions for Edwards Lifesciences Corp (EW). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Edwards Lifesciences Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Edwards Lifesciences Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 31
2023
|
Michael A Mussallem Director |
BUY
Bona fide gift
|
Indirect |
49,766
+1.34%
|
-
|
|
Aug 31
2023
|
Michael A Mussallem Director |
SELL
Bona fide gift
|
Direct |
49,766
-91.73%
|
-
|
|
Aug 29
2023
|
Daveen Chopra CVP, TMTT |
SELL
Open market or private sale
|
Direct |
1,500
-5.89%
|
$114,000
$76.69 P/Share
|
|
Aug 14
2023
|
Larry L Wood Global President TAVR & Surg |
SELL
Open market or private sale
|
Direct |
6,421
-2.92%
|
$507,259
$79.3 P/Share
|
|
Aug 14
2023
|
Larry L Wood Global President TAVR & Surg |
BUY
Exercise of conversion of derivative security
|
Direct |
6,421
+2.83%
|
$288,945
$45.28 P/Share
|
|
Aug 14
2023
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
SELL
Open market or private sale
|
Direct |
4,500
-10.23%
|
$355,500
$79.3 P/Share
|
|
Aug 14
2023
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
BUY
Exercise of conversion of derivative security
|
Direct |
4,500
+9.28%
|
$162,000
$36.75 P/Share
|
|
Aug 10
2023
|
Heisz Leslie Stone Director |
SELL
Open market or private sale
|
Direct |
3,303
-10.91%
|
$257,634
$78.87 P/Share
|
|
Aug 09
2023
|
Catherine M. Szyman CVP, Critical Care |
SELL
Open market or private sale
|
Direct |
5,000
-12.56%
|
$390,000
$78.64 P/Share
|
|
Aug 09
2023
|
Catherine M. Szyman CVP, Critical Care |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+11.16%
|
$180,000
$36.75 P/Share
|
|
Aug 07
2023
|
Michael A Mussallem Director |
SELL
Open market or private sale
|
Direct |
29,350
-17.62%
|
$2,348,000
$80.2 P/Share
|
|
Aug 07
2023
|
Michael A Mussallem Director |
BUY
Exercise of conversion of derivative security
|
Direct |
29,350
+25.98%
|
$1,056,600
$36.75 P/Share
|
|
Jul 31
2023
|
Bernard J Zovighian CEO |
BUY
Discretionary transaction
|
Direct |
2,558
+5.15%
|
$212,314
$83.54 P/Share
|
|
Jul 31
2023
|
Scott B. Ullem CVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
7,255
-27.37%
|
$609,420
$84.35 P/Share
|
|
Jul 31
2023
|
Scott B. Ullem CVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,255
+21.49%
|
$261,180
$36.75 P/Share
|
|
Jul 14
2023
|
Larry L Wood Global President TAVR & Surg |
SELL
Open market or private sale
|
Direct |
8,660
-3.89%
|
$796,720
$92.94 P/Share
|
|
Jul 14
2023
|
Larry L Wood Global President TAVR & Surg |
BUY
Exercise of conversion of derivative security
|
Direct |
8,660
+3.75%
|
$389,700
$45.28 P/Share
|
|
Jul 14
2023
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
SELL
Open market or private sale
|
Direct |
3,500
-8.14%
|
$322,000
$92.94 P/Share
|
|
Jul 14
2023
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
BUY
Exercise of conversion of derivative security
|
Direct |
3,500
+7.53%
|
$126,000
$36.75 P/Share
|
|
Jul 10
2023
|
Catherine M. Szyman CVP, Critical Care |
SELL
Open market or private sale
|
Direct |
5,000
-12.56%
|
$450,000
$90.52 P/Share
|
|
Jul 10
2023
|
Catherine M. Szyman CVP, Critical Care |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+11.16%
|
$180,000
$36.75 P/Share
|
|
Jul 07
2023
|
Catherine M. Szyman CVP, Critical Care |
SELL
Payment of exercise price or tax liability
|
Direct |
252
-0.72%
|
$22,680
$90.46 P/Share
|
|
Jul 07
2023
|
Jean Luc M Lemercier CVP, EMEACLA and JAPAC |
SELL
Payment of exercise price or tax liability
|
Direct |
81
-0.05%
|
$7,290
$90.46 P/Share
|
|
Jul 05
2023
|
Michael A Mussallem Director |
SELL
Open market or private sale
|
Direct |
29,350
-18.86%
|
$2,641,500
$90.92 P/Share
|
|
Jul 05
2023
|
Michael A Mussallem Director |
BUY
Exercise of conversion of derivative security
|
Direct |
29,350
+25.98%
|
$1,056,600
$36.75 P/Share
|
|
Jun 30
2023
|
Scott B. Ullem CVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
7,255
-27.37%
|
$674,715
$93.27 P/Share
|
|
Jun 30
2023
|
Scott B. Ullem CVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,255
+21.49%
|
$261,180
$36.75 P/Share
|
|
Jun 14
2023
|
Larry L Wood Global President TAVR & Surg |
SELL
Open market or private sale
|
Direct |
8,660
-1.96%
|
$779,400
$90.29 P/Share
|
|
Jun 14
2023
|
Larry L Wood Global President TAVR & Surg |
BUY
Exercise of conversion of derivative security
|
Direct |
8,660
+3.75%
|
$389,700
$45.28 P/Share
|
|
Jun 14
2023
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
SELL
Open market or private sale
|
Direct |
3,500
-8.14%
|
$311,500
$89.77 P/Share
|
|
Jun 14
2023
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
BUY
Exercise of conversion of derivative security
|
Direct |
3,500
+7.53%
|
$126,000
$36.75 P/Share
|
|
Jun 13
2023
|
Catherine M. Szyman CVP, Critical Care |
SELL
Open market or private sale
|
Direct |
5,000
-12.48%
|
$425,000
$85.81 P/Share
|
|
Jun 13
2023
|
Catherine M. Szyman CVP, Critical Care |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+11.1%
|
$180,000
$36.75 P/Share
|
|
Jun 01
2023
|
Michael A Mussallem Director |
SELL
Open market or private sale
|
Direct |
29,350
-9.09%
|
$2,465,400
$84.36 P/Share
|
|
Jun 01
2023
|
Michael A Mussallem Director |
BUY
Exercise of conversion of derivative security
|
Direct |
29,350
+20.25%
|
$1,056,600
$36.75 P/Share
|
|
May 24
2023
|
Larry L Wood Global President TAVR & Surg |
SELL
Open market or private sale
|
Direct |
6,421
-2.92%
|
$539,364
$84.23 P/Share
|
|
May 24
2023
|
Larry L Wood Global President TAVR & Surg |
BUY
Exercise of conversion of derivative security
|
Direct |
6,421
+2.83%
|
$288,945
$45.28 P/Share
|
|
May 17
2023
|
Scott B. Ullem CVP, Chief Financial Officer |
BUY
Bona fide gift
|
Indirect |
8,496
+3.09%
|
-
|
|
May 17
2023
|
Scott B. Ullem CVP, Chief Financial Officer |
SELL
Bona fide gift
|
Direct |
8,496
-30.62%
|
-
|
|
May 12
2023
|
Nicholas J Valeriani Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,803
+3.91%
|
-
|
|
May 12
2023
|
Michael A Mussallem Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,485
+4.95%
|
-
|
|
May 12
2023
|
Heisz Leslie Stone Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,803
+8.47%
|
-
|
|
May 12
2023
|
Kieran Gallahue Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,701
+34.76%
|
-
|
|
May 12
2023
|
Paul A Laviolette Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,803
+26.64%
|
-
|
|
May 12
2023
|
Steven R Loranger Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,701
+3.19%
|
-
|
|
May 12
2023
|
Martha H. Marsh Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,803
+8.08%
|
-
|
|
May 12
2023
|
Ramona Sequeira Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,803
+35.45%
|
-
|
|
May 11
2023
|
Scott B. Ullem CVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,450
+25.41%
|
-
|
|
May 11
2023
|
Daveen Chopra CVP, TMTT |
BUY
Grant, award, or other acquisition
|
Direct |
6,475
+20.28%
|
-
|
|
May 11
2023
|
Catherine M. Szyman CVP, Critical Care |
BUY
Grant, award, or other acquisition
|
Direct |
6,525
+15.69%
|
-
|